JP5492563B2 - トランスフェリン融合タンパク質ライブラリー - Google Patents

トランスフェリン融合タンパク質ライブラリー Download PDF

Info

Publication number
JP5492563B2
JP5492563B2 JP2009540888A JP2009540888A JP5492563B2 JP 5492563 B2 JP5492563 B2 JP 5492563B2 JP 2009540888 A JP2009540888 A JP 2009540888A JP 2009540888 A JP2009540888 A JP 2009540888A JP 5492563 B2 JP5492563 B2 JP 5492563B2
Authority
JP
Japan
Prior art keywords
protein
transferrin
genbank accession
accession number
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009540888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512160A5 (enExample
JP2010512160A (ja
Inventor
ジョン ターナー アンドリュー
ワング ベイヤング
Original Assignee
バイオレクシス ファーマシューティカル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオレクシス ファーマシューティカル コーポレーション filed Critical バイオレクシス ファーマシューティカル コーポレーション
Publication of JP2010512160A publication Critical patent/JP2010512160A/ja
Publication of JP2010512160A5 publication Critical patent/JP2010512160A5/ja
Application granted granted Critical
Publication of JP5492563B2 publication Critical patent/JP5492563B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009540888A 2006-12-12 2007-12-07 トランスフェリン融合タンパク質ライブラリー Expired - Fee Related JP5492563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93495106P 2006-12-12 2006-12-12
US60/934,951 2006-12-12
PCT/IB2007/003908 WO2008072075A2 (en) 2006-12-12 2007-12-07 Transferrin fusion protein libraries

Publications (3)

Publication Number Publication Date
JP2010512160A JP2010512160A (ja) 2010-04-22
JP2010512160A5 JP2010512160A5 (enExample) 2012-08-30
JP5492563B2 true JP5492563B2 (ja) 2014-05-14

Family

ID=39362844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540888A Expired - Fee Related JP5492563B2 (ja) 2006-12-12 2007-12-07 トランスフェリン融合タンパク質ライブラリー

Country Status (13)

Country Link
US (1) US8822639B2 (enExample)
EP (2) EP2114999A2 (enExample)
JP (1) JP5492563B2 (enExample)
KR (1) KR20090098880A (enExample)
CN (1) CN101622274A (enExample)
AU (1) AU2007331195A1 (enExample)
CA (1) CA2673085C (enExample)
ES (1) ES2535358T3 (enExample)
IL (1) IL198815A0 (enExample)
MX (1) MX2009006398A (enExample)
NO (1) NO20092591L (enExample)
WO (1) WO2008072075A2 (enExample)
ZA (1) ZA200904757B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CN102258767B (zh) * 2010-05-24 2013-05-15 黄敏铨 促进伤口愈合的组合物
US20130251740A1 (en) * 2010-10-26 2013-09-26 Rockefeller University (The) Immunogenic agents
CA2825641C (en) * 2011-02-02 2016-10-11 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
SI3401402T1 (sl) * 2012-06-08 2021-03-31 Alkermes Pharma Ireland Limited Ligandi modificirani s krožno permutacijo kot agonisti in antagonisti
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
CN107075507B (zh) * 2014-11-10 2021-08-24 小利兰斯坦福大学理事会 用于在细胞表面上表达多肽的组合物和方法
EP3438254A4 (en) * 2016-03-30 2019-10-16 Kaneka Corporation POLYPEPTIDE WITH ENDONUCLEASE ACTIVITY AND MANUFACTURING METHOD THEREFOR
BR112019003622A2 (pt) * 2016-08-25 2019-05-21 Jcr Pharmaceuticals Co., Ltd. método para produção de uma proteína de fusão.
JP7627910B2 (ja) * 2018-12-21 2025-02-07 フエー・イー・ベー・フエー・ゼツト・ウエー サイトカイン及び足場タンパク質を含む融合タンパク質
CN113045670B (zh) * 2019-12-27 2022-11-01 华南农业大学 一种可溶性鸡α干扰素融合蛋白及其生产方法与应用
EP4314073A4 (en) 2021-03-24 2025-02-19 Alkermes, Inc. Upar antibodies and fusion proteins with the same
US20250041398A1 (en) * 2021-12-16 2025-02-06 Thomas Jefferson University A therapeutic against crimean-congo hemorrhagic fever virus

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
AU600885B2 (en) 1984-05-25 1990-08-30 Zymogenetics Inc. Stable DNA constructs
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5026651A (en) 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5346989A (en) 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
US5347849A (en) 1990-08-30 1994-09-20 Tanknology Corporation International Water sensor that detects tank or vessel leakage
US5986067A (en) 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
EP0611306B1 (en) 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
EP0682710B1 (en) 1993-02-10 2003-10-29 Unilever Plc Isolation process using immobilized proteins with specific binding capacities
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5603933A (en) 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
EP0831873A4 (en) 1995-06-07 2002-07-17 Trimeris Inc COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6699677B1 (en) 1999-12-20 2004-03-02 Chemocentryx, Inc. Tethered ligands and methods of use
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
ATE490969T1 (de) 2001-08-30 2010-12-15 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine
US20070031440A1 (en) 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2004019872A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
US20060105387A1 (en) 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
CN1713920A (zh) 2002-08-30 2005-12-28 比奥雷克西斯药物公司 被修饰的转铁蛋白融合蛋白
ES2337245T3 (es) * 2002-08-30 2010-04-22 Biorexis Pharmaceutical Corporation Bibliotecas de proteinas de fucion de la transferrina.
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20060205037A1 (en) 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
EP1663278A4 (en) 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp EPO MIMETIC PEPTIDES AND FUSION PROTEINS
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
JP2008546392A (ja) * 2005-06-17 2008-12-25 バイオレクシス ファーマシューティカル コーポレーション 固定されたトランスフェリン融合タンパク質ライブラリー
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白

Also Published As

Publication number Publication date
KR20090098880A (ko) 2009-09-17
EP2114999A2 (en) 2009-11-11
US20110086768A1 (en) 2011-04-14
MX2009006398A (es) 2009-06-23
CA2673085A1 (en) 2008-06-19
EP2479189B1 (en) 2015-02-25
CN101622274A (zh) 2010-01-06
US8822639B2 (en) 2014-09-02
ES2535358T3 (es) 2015-05-08
AU2007331195A1 (en) 2008-06-19
IL198815A0 (en) 2011-08-01
WO2008072075A3 (en) 2008-11-06
EP2479189A1 (en) 2012-07-25
WO2008072075A2 (en) 2008-06-19
NO20092591L (no) 2009-09-11
CA2673085C (en) 2013-10-15
JP2010512160A (ja) 2010-04-22
ZA200904757B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
JP5492563B2 (ja) トランスフェリン融合タンパク質ライブラリー
Rich et al. Survey of the year 2001 commercial optical biosensor literature
EP1427750B1 (en) Modified transferrin fusion proteins
EP1545595B1 (en) Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
JP6146821B2 (ja) 修飾ユビキチンに基づく二量体型結合タンパク質
CN116426490A (zh) 淋巴细胞转导及其扩增调节的方法与组合物
CA2430528A1 (en) Hybrid antibodies
JP2014523238A (ja) インターフェロンと標的化修飾ユビキチンタンパク質とを含むヒト融合タンパク質
US20060105387A1 (en) Transferrin fusion proteins libraries
US20230027899A1 (en) Cd122 with altered icd stat signaling
US20090275481A1 (en) Anchored Transferrin Fusion Protein Libraries
EP1539221B1 (en) Transferrin fusion protein libraries
CN101519449A (zh) 经修饰的运铁蛋白融合蛋白
HK1135992A (en) Transferrin fusion protein libraries
HK1131625A (en) Modified transferrin fusion proteins
WO2011132939A2 (ko) Rtk에 특이적으로 결합하는 rtk-bpb

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140303

R150 Certificate of patent or registration of utility model

Ref document number: 5492563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees